Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on March 24, 2026. The filing discloses corporate governance actions taken by the Compensation Committee of the Board of Directors regarding executive and employee compensation structures effective for the 2026 fiscal year.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the approval of a new cash bonus plan and an amendment to the Chief Executive Officer's employment agreement.
Material Changes
- 2026 Corporate Bonus Plan Approval: The Compensation Committee approved a new cash bonus plan effective January 1, 2026. The plan incentivizes employees based on corporate and individual performance objectives.
- CEO Compensation Adjustment: The bonus target for Jason A. Okazaki, Chief Executive Officer and President, was increased from 60% to 65% of his base salary, effective for fiscal year 2026.
Guidance, Outlook, and Management Commentary
The filing outlines the mechanics of the new 2026 Corporate Bonus Plan:
- Eligibility: Employees commencing employment by October 31 of the performance period and designated by the Committee or CEO.
- Performance Metrics: Bonuses are based on Corporate Objectives (financial and operational) and Individual Objectives. Weights vary by role:
- CEO: 100% Corporate Objectives.
- C-Level/SVP/VP: 75% Corporate, 25% Individual.
- Executive Director/Director: 50% Corporate, 50% Individual.
- Associate Director and Below: 25% Corporate, 75% Individual.
- Payout Structure: Targets range from up to 75% of base salary for the CEO, 30-55% for other Executive Participants, and up to 28% for Non-Executive Participants. Actual payouts can range from 0 to 1.5 times the target.
- Timing: Bonuses are expected to be paid in the first quarter following the performance period, no later than March 15.
Investor Verification Checklist
- Review the full text of the 2026 Corporate Bonus Plan (Exhibit 10.1) for specific performance metrics and clawback provisions.
- Examine Amendment No. 1 to the CEO's employment agreement (Exhibit 10.2) for details on the bonus target increase and any other modified terms.
- Monitor future filings for the specific Corporate Objectives approved by the Board within 90 days of the performance period start.
- Verify the impact of the increased CEO bonus target on total executive compensation expenses in upcoming quarterly reports.